POCI

Business Context and Reporting Period

Precision Optics Corporation, Inc. (PEYE) filed its Form 10-Q for the quarterly period ended March 31, 2009. The company designs and manufactures advanced optical instruments, including micro-optics and medical devices such as endoscopes. The company is classified as a smaller reporting company and a shell company is not applicable. The financial statements reflect a 1-for-25 reverse stock split effective December 11, 2008.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenues increased 39.4% quarter-over-quarter (QoQ) and 8.3% year-over-year (YoY) for the nine-month period. The QoQ increase was driven by sales of an advanced surgical visualization system, while the nine-month increase was driven by optical components and fiber scopes.
• Margin Expansion: Gross profit margin improved significantly from 25.6% to 36.7% QoQ and from 24.1% to 44.6% for the nine-month period, attributed to manufacturing efficiencies and product mix changes.
• Expense Management: Selling, General, and Administrative (SG&A) expenses decreased 20.5% QoQ and 24.1% YoY due to workforce reductions. However, Research and Development (R&D) expenses increased 90.2% QoQ due to specific development initiatives, though they decreased 19.0% on a nine-month basis.
• Interest Expense: Interest expense increased to $64,875 for the quarter and $388,925 for the nine months, compared to zero in the prior year periods, due to the amortization of debt discount on convertible notes issued in June 2008.
• Asset Sales: The company recorded a $40,361 gain on the sale of assets in the current quarter. In the prior year, a $210,549 gain was recorded from the sale of a product line.

Outlook, Risks, and Management Commentary

• Going Concern: The company has sustained recurring net losses and negative cash flows. Management states these factors raise substantial doubt about the company's ability to continue as a going concern. Financial statements are prepared assuming the company will continue operations, but no adjustments have been made for potential liquidation.
• Liquidity: Cash and cash equivalents were $509,475 as of March 31, 2009. The company anticipates settling approximately $274,000 of deferred officer salaries and director consulting expenses via restricted stock rather than cash. If additional revenues are not achieved, further cost reductions or capital raising will be necessary.
• Debt Obligations: The company has $600,000 principal in 10% Senior Secured Convertible Notes due June 25, 2010. Contractual cash commitments for principal and interest in 2010 total $720,000, though this may be reduced if notes are converted to stock.
• Internal Controls: Management identified a material weakness in internal controls due to a lack of segregation of duties (only 1.5 persons performing accounting duties). Remediation includes higher-level reviews by the President and Board of Directors.
• Product Pipeline: Future growth depends on the commercialization of Lenslock technology endoscopes, micro-precision lenses, and night vision lenses. Management expects operating losses to continue through fiscal year 2009 until sales reach breakeven levels.

Investor Verification Checklist

• Verify the sufficiency of cash reserves ($509,475) to cover operations and the $720,000 debt obligation due in 2010.
• Confirm the status of the Form S-1 registration statement filed in December 2008 (amended April 2009) regarding the registration of shares underlying convertible notes and warrants.
• Assess the sustainability of the 44.6% gross margin, which relies on specific product mix and manufacturing efficiencies.
• Monitor the effectiveness of the remediation plan for the material weakness in internal controls over financial reporting.
• Review the timeline for the conversion of the Senior Secured Convertible Notes to avoid a cash liquidity crisis at maturity.